Cynthia Araradian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cynthia Araradian has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Emmett Hunnicutt
School of Medicine, Oregon Health & Science University, Portland, OR 97239, USA
2 shared publications - Maura Walsh
Department of Surgery, Oregon Health & Science University, Portland, OR 97239, USA
2 shared publications - Sandy Hwang Fang
Department of Surgery, Oregon Health & Science University, Portland, OR 97239, USA
2 shared publications - Vassiliki Liana Tsikitis
Department of Surgery, Oregon Health & Science University, Portland, OR 97239, USA
2 shared publications Adel Kardosh
Department of Medicine, Hematology/Medical Oncology, Oregon Health and Science University, Portland, Oregon
1 shared publication- Alan L. Nager
Division of Emergency and Transport Medicine, Children's Hospital Los Angeles, Los Angeles, Calif; Department of Pediatrics, Keck School of Medicine of the University of Southern California, Los Angeles, Calif
1 shared publication
Latest Publications
- Open Access
Identification of Factors That Determine Adherence for Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Background: Locally advanced rectal cancer (LARC) treatment has shifted from the utilization of neoadjuvant chemoradiation (NACRT), followed by total mesorectal excision (TME) and adjuvant chemotherapy (AC) to the implementation of total neoadjuvant therapy (TNT). This transition was influenced by data from multiple studies reporting suboptimal compliance rates to adjuvant chemotherapy. As a result, a paradigm shift to TNT occurred, consisting of chemoradiation with chemotherapy, based on the RAPIDO and PRODIGE-23 studies. Methods: Following IRB approval, a single-institution retrospective chart review was conducted at a tertiary care academic institution for patients with LARC. Demographic, clinical, and treatment data were collected using REDCap. Patients were excluded if under 18 years of age, pregnant, or had stage 1 or metastatic rectal cancer. The primary objective was to evaluate TNT adherence; secondary objectives assessed adherence associations with demographic and clinical variables. Results: Two hundred twenty-nine patients with rectal cancer were initially included in the database, including 153 patients with LARC from 2019 to 2024. One hundred twenty-seven patients underwent TNT with an adherence rate of 87.5%. Statistically significant variables that contributed to adherence include male gender (p = 0.04) and non-use of recreational drugs (p = 0.04). Conclusions: This is the first real-world study assessing TNT adherence. The observed 87.5% adherence rate represents a significant improvement over historical data in which patients were treated with NACRT/TME/AC. Statistically significant variables that contributed to TNT adherence included male gender and non-use of recreational drugs. These factors may provide insight into gender differences and behavioral patterns that put patients in an at-risk category for non-adherence.
Open AccessIdentification of Factors That Determine Adherence for Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Background: Locally advanced rectal cancer (LARC) treatment has shifted from the utilization of neoadjuvant chemoradiation (NACRT), followed by total mesorectal excision (TME) and adjuvant chemotherapy (AC) to the implementation of total neoadjuvant therapy (TNT). This transition was influenced by data from multiple studies reporting suboptimal compliance rates to adjuvant chemotherapy. As a result, a paradigm shift to TNT occurred, consisting of chemoradiation with chemotherapy, based on the RAPIDO and PRODIGE-23 studies. Methods: Following IRB approval, a single-institution retrospective chart review was conducted at a tertiary care academic institution for patients with LARC. Demographic, clinical, and treatment data were collected using REDCap. Patients were excluded if under 18 years of age, pregnant, or had stage 1 or metastatic rectal cancer. The primary objective was to evaluate TNT adherence; secondary objectives assessed adherence associations with demographic and clinical variables. Results: Two hundred twenty-nine patients with rectal cancer were initially included in the database, including 153 patients with LARC from 2019 to 2024. One hundred twenty-seven patients underwent TNT with an adherence rate of 87.5%. Statistically significant variables that contributed to adherence include male gender (p = 0.04) and non-use of recreational drugs (p = 0.04). Conclusions: This is the first real-world study assessing TNT adherence. The observed 87.5% adherence rate represents a significant improvement over historical data in which patients were treated with NACRT/TME/AC. Statistically significant variables that contributed to TNT adherence included male gender and non-use of recreational drugs. These factors may provide insight into gender differences and behavioral patterns that put patients in an at-risk category for non-adherence.
- 9 September 2025
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 68 (12) , 1393-1402
Pilot Study: Identification of the T-Cell Tumor Microenvironment of Premalignant and Malignant Anal Lesions
BACKGROUND: Anal squamous-cell cancer incidence has risen 2.2% each year during the past decade. Current screening methods include anal cytology and high-resolution anoscopy but are burdened with sampling errors and patient discomfort. OBJECTIVE: To analyze the T-cell microenvironment of normal, premalignant (including low- and high-grade squamous intraepithelial lesions), and cancerous tissues. DESIGN: Institutional review board–approved prospective study of patients with anal dysplasia and cancer. Normal, dysplastic, and/or cancerous tissues were obtained from patients. Tissue was digested to obtain a single-cell suspension. Flow cytometry analysis was performed on matched patient samples to evaluate T-cell biomarkers. SETTINGS: A single tertiary-care academic center. PATIENTS: Patients older than 18 years and scheduled to undergo high-resolution anoscopy, examination under anesthesia, or abdominoperineal resection were included. MAIN OUTCOME MEASURES: Descriptive statistics were used to understand differences in the tumor microenvironment of normal, premalignant, and malignant tissue. RESULTS: Twenty patients underwent immunophenotyping. Normal tissue was characterized by the presence of a few infiltrating lymphocytes. Anal cancers contained 30% to 50% regulatory T cells, whereas these cells were infrequent in dysplasia. In anal cancer, conventional CD4 + T cells expressed high levels of inducible co-stimulator and programmed cell death protein-, reflective of tumor antigen recognition. In premalignant lesions, CD4 + conventional T cells also expressed inducible co-stimulator and programmed cell death protein-1 but lacked coexpression of chronic activation and proliferation markers. CD8 + T cells with a CD103 + CD39 + phenotype, indicative of chronic stimulation and tissue residency, were increased in anal cancer. LIMITATIONS: This study was limited by its small sample size. Results may not be generalizable to a larger population. CONCLUSIONS: The data demonstrate that T-cell infiltrates differ between normal, premalignant, and malignant lesions, with tissue from anal squamous-cell cancers containing activated, chronically stimulated T cells. Future clinical diagnostic technology would yield a T-cell pathological footprint that differentiates between premalignant and malignant lesions, in addition to the development of a less invasive serum T-cell biomarker test. See Video Abstract . ESTUDIO PILOTO: IDENTIFICACIÓN DEL MICROAMBIENTE TUMORAL DE CÉLULAS T EN LESIONES ANALES PREMALIGNAS Y MALIGNAS: ANTECEDENTES: La incidencia del cáncer de células escamosas anales ha aumentado un 2,2 % cada año durante la última década. Las pruebas de detección actuales incluyen citología anal y anoscopia de alta resolución, pero presentan errores de muestreo y molestias para el paciente. OBJETIVO: Analizar el microambiente de las células T en casos normales, premalignos, incluidas las lesiones intraepiteliales escamosas de bajo y alto grado, y cancerosos. DISEÑO: Estudio prospectivo aprobado por el Comité de Ética en Investigación (IRB) de pacientes con displasia anal y cáncer. Se obtienen tejidos normales, displásicos y/o cancerosos de los pacientes. El tejido se digiere para obtener una suspensión de células individuales. Se realiza un análisis de citometría de flujo en muestras de pacientes emparejadas para evaluar los biomarcadores de las células T. ENTORNO: Un único centro académico de atención terciaria. PACIENTES: Mayores de 18 años y programados para someterse a una anoscopia de alta resolución, un examen bajo anestesia o una resección abdominoperineal. PRINCIPALES MEDIDAS DE RESULTADOS: Se utilizan estadísticas descriptivas para comprender las diferencias en el microambiente tumoral del tejido normal, premaligno y maligno. RESULTADOS: Veinte pacientes se sometieron a inmunofenotipado. El tejido normal se caracterizó por la presencia de pocos linfocitos infiltrantes. Los cánceres anales contenían entre un 30 % y un 50 % de células T reguladoras, que eran poco frecuentes en la displasia. En el cáncer anal, las células T CD4+ convencionales expresaban niveles elevados de ICOS y PD-1, lo que reflejaba el reconocimiento del antígeno tumoral. En las lesiones premalignas, las células T CD4+ convencionales también expresaban ICOS y PD-1, pero carecían de la coexpresión de marcadores de activación crónica y proliferación. Las células T CD8+ con un fenotipo CD103 + CD39 + , indicativo de estimulación crónica y residencia en el tejido, aumentaban en el cáncer anal. LIMITACIONES: Este estudio está limitado por el pequeño tamaño de la muestra. Es posible que los resultados no sean generalizables a una población más amplia. CONCLUSIONES: Los datos demuestran que los infiltrados de células T difieren entre las lesiones normales, premalignas y malignas, y que el tejido del cáncer de células escamosas anal contiene células T activadas y estimuladas crónicamente. La futura tecnología de diagnóstico clínico proporcionaría una huella patológica de las células T para diferenciar entre lesiones premalignas y malignas, además de la creación de una prueba de biomarcadores de células T en suero menos invasiva. (AI-generated translation )
- 9 September 2025
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 68 (12) , 1393-1402
Pilot Study: Identification of the T-Cell Tumor Microenvironment of Premalignant and Malignant Anal Lesions
BACKGROUND: Anal squamous-cell cancer incidence has risen 2.2% each year during the past decade. Current screening methods include anal cytology and high-resolution anoscopy but are burdened with sampling errors and patient discomfort. OBJECTIVE: To analyze the T-cell microenvironment of normal, premalignant (including low- and high-grade squamous intraepithelial lesions), and cancerous tissues. DESIGN: Institutional review board–approved prospective study of patients with anal dysplasia and cancer. Normal, dysplastic, and/or cancerous tissues were obtained from patients. Tissue was digested to obtain a single-cell suspension. Flow cytometry analysis was performed on matched patient samples to evaluate T-cell biomarkers. SETTINGS: A single tertiary-care academic center. PATIENTS: Patients older than 18 years and scheduled to undergo high-resolution anoscopy, examination under anesthesia, or abdominoperineal resection were included. MAIN OUTCOME MEASURES: Descriptive statistics were used to understand differences in the tumor microenvironment of normal, premalignant, and malignant tissue. RESULTS: Twenty patients underwent immunophenotyping. Normal tissue was characterized by the presence of a few infiltrating lymphocytes. Anal cancers contained 30% to 50% regulatory T cells, whereas these cells were infrequent in dysplasia. In anal cancer, conventional CD4 + T cells expressed high levels of inducible co-stimulator and programmed cell death protein-, reflective of tumor antigen recognition. In premalignant lesions, CD4 + conventional T cells also expressed inducible co-stimulator and programmed cell death protein-1 but lacked coexpression of chronic activation and proliferation markers. CD8 + T cells with a CD103 + CD39 + phenotype, indicative of chronic stimulation and tissue residency, were increased in anal cancer. LIMITATIONS: This study was limited by its small sample size. Results may not be generalizable to a larger population. CONCLUSIONS: The data demonstrate that T-cell infiltrates differ between normal, premalignant, and malignant lesions, with tissue from anal squamous-cell cancers containing activated, chronically stimulated T cells. Future clinical diagnostic technology would yield a T-cell pathological footprint that differentiates between premalignant and malignant lesions, in addition to the development of a less invasive serum T-cell biomarker test. See Video Abstract . ESTUDIO PILOTO: IDENTIFICACIÓN DEL MICROAMBIENTE TUMORAL DE CÉLULAS T EN LESIONES ANALES PREMALIGNAS Y MALIGNAS: ANTECEDENTES: La incidencia del cáncer de células escamosas anales ha aumentado un 2,2 % cada año durante la última década. Las pruebas de detección actuales incluyen citología anal y anoscopia de alta resolución, pero presentan errores de muestreo y molestias para el paciente. OBJETIVO: Analizar el microambiente de las células T en casos normales, premalignos, incluidas las lesiones intraepiteliales escamosas de bajo y alto grado, y cancerosos. DISEÑO: Estudio prospectivo aprobado por el Comité de Ética en Investigación (IRB) de pacientes con displasia anal y cáncer. Se obtienen tejidos normales, displásicos y/o cancerosos de los pacientes. El tejido se digiere para obtener una suspensión de células individuales. Se realiza un análisis de citometría de flujo en muestras de pacientes emparejadas para evaluar los biomarcadores de las células T. ENTORNO: Un único centro académico de atención terciaria. PACIENTES: Mayores de 18 años y programados para someterse a una anoscopia de alta resolución, un examen bajo anestesia o una resección abdominoperineal. PRINCIPALES MEDIDAS DE RESULTADOS: Se utilizan estadísticas descriptivas para comprender las diferencias en el microambiente tumoral del tejido normal, premaligno y maligno. RESULTADOS: Veinte pacientes se sometieron a inmunofenotipado. El tejido normal se caracterizó por la presencia de pocos linfocitos infiltrantes. Los cánceres anales contenían entre un 30 % y un 50 % de células T reguladoras, que eran poco frecuentes en la displasia. En el cáncer anal, las células T CD4+ convencionales expresaban niveles elevados de ICOS y PD-1, lo que reflejaba el reconocimiento del antígeno tumoral. En las lesiones premalignas, las células T CD4+ convencionales también expresaban ICOS y PD-1, pero carecían de la coexpresión de marcadores de activación crónica y proliferación. Las células T CD8+ con un fenotipo CD103 + CD39 + , indicativo de estimulación crónica y residencia en el tejido, aumentaban en el cáncer anal. LIMITACIONES: Este estudio está limitado por el pequeño tamaño de la muestra. Es posible que los resultados no sean generalizables a una población más amplia. CONCLUSIONES: Los datos demuestran que los infiltrados de células T difieren entre las lesiones normales, premalignas y malignas, y que el tejido del cáncer de células escamosas anal contiene células T activadas y estimuladas crónicamente. La futura tecnología de diagnóstico clínico proporcionaría una huella patológica de las células T para diferenciar entre lesiones premalignas y malignas, además de la creación de una prueba de biomarcadores de células T en suero menos invasiva. (AI-generated translation )
- Open Access
A Systematic Review Defining Early Anal Squamous Cell Carcinoma and Identifying Treatment
Background: Anal cancer screening has allowed for the diagnosis of early-stage anal cancers; however, guidelines for the treatment of early anal cancers remain mixed given the scarcity of clinical trials and data. Management ranges from chemoradiation therapy to local surgical excision. Methods: This paper’s objective is to clarify the definition of early anal cancer and its management. Approval for this systematic review was obtained through PROSPERO [CRD42022304327]. Three independent reviewers screened the studies and performed data analysis, with conflicts resolved by a fourth reviewer. All information is presented according to the Preferred Reporting Item for Systematic Reviews and Meta-Analysis (PRISMA). The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) criteria were used to assess the certainty of the evidence. Results: The MEDLINE, EMBASE and Cochrane databases were queried with 628 articles screened. A total of 15 articles were selected for inclusion. Early anal cancer was most often defined as T1-2N0M0 anal cancer but also included Superficially Invasive Squamous Cell Carcinoma (SISCCA). There were various treatments assessed for outcomes including local excision, chemoradiation, and radiation. The studies reported overall survival, cancer-specific survival, recurrence-free survival, and/or colostomy-free survival, leading to significant heterogeneity amongst the studies. No meta-analysis was possible. Conclusions: Poor-quality studies exist for the evaluation of the most effective treatment modality for early anal cancer. Surgical excision alone with adequate margins has equivocal results, but data is poor. Chemoradiation is successful but may be overtreatment. Randomized controlled studies are needed, as screening will result in earlier anal cancer diagnoses.
Open AccessA Systematic Review Defining Early Anal Squamous Cell Carcinoma and Identifying Treatment
Background: Anal cancer screening has allowed for the diagnosis of early-stage anal cancers; however, guidelines for the treatment of early anal cancers remain mixed given the scarcity of clinical trials and data. Management ranges from chemoradiation therapy to local surgical excision. Methods: This paper’s objective is to clarify the definition of early anal cancer and its management. Approval for this systematic review was obtained through PROSPERO [CRD42022304327]. Three independent reviewers screened the studies and performed data analysis, with conflicts resolved by a fourth reviewer. All information is presented according to the Preferred Reporting Item for Systematic Reviews and Meta-Analysis (PRISMA). The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) criteria were used to assess the certainty of the evidence. Results: The MEDLINE, EMBASE and Cochrane databases were queried with 628 articles screened. A total of 15 articles were selected for inclusion. Early anal cancer was most often defined as T1-2N0M0 anal cancer but also included Superficially Invasive Squamous Cell Carcinoma (SISCCA). There were various treatments assessed for outcomes including local excision, chemoradiation, and radiation. The studies reported overall survival, cancer-specific survival, recurrence-free survival, and/or colostomy-free survival, leading to significant heterogeneity amongst the studies. No meta-analysis was possible. Conclusions: Poor-quality studies exist for the evaluation of the most effective treatment modality for early anal cancer. Surgical excision alone with adequate margins has equivocal results, but data is poor. Chemoradiation is successful but may be overtreatment. Randomized controlled studies are needed, as screening will result in earlier anal cancer diagnoses.
- Open Access
Advances in the Management, Treatment, and Surveillance of Anal Squamous Cell Cancer
Anal cancer is a rare diagnosis, but incidence has been increasing over the past decade. Anal cancer is associated with the human papilloma virus (HPV), specifically the high-risk subtypes of 16 and 18. In addition, the precursor lesion for anal cancer is high-grade squamous intraepithelial lesions (HSILs) and its treatment and surveillance has been emphasized over the last 5 years. The current standard of care for anal cancer includes the Nigro protocol, concurrent chemoradiation, typically radiation with systemic mitomycin and 5-fluorouracil (5-FU). The protocol’s efficacy laid the foundation for sphincter preservation and non-operative management. This review will detail the essential clinical trials in the treatment and surveillance of premalignant lesions and anal squamous cell cancer, including alterations in radiation dosing, systemic chemotherapy, and immunotherapy over the last several decades.
Open AccessAdvances in the Management, Treatment, and Surveillance of Anal Squamous Cell Cancer
Anal cancer is a rare diagnosis, but incidence has been increasing over the past decade. Anal cancer is associated with the human papilloma virus (HPV), specifically the high-risk subtypes of 16 and 18. In addition, the precursor lesion for anal cancer is high-grade squamous intraepithelial lesions (HSILs) and its treatment and surveillance has been emphasized over the last 5 years. The current standard of care for anal cancer includes the Nigro protocol, concurrent chemoradiation, typically radiation with systemic mitomycin and 5-fluorouracil (5-FU). The protocol’s efficacy laid the foundation for sphincter preservation and non-operative management. This review will detail the essential clinical trials in the treatment and surveillance of premalignant lesions and anal squamous cell cancer, including alterations in radiation dosing, systemic chemotherapy, and immunotherapy over the last several decades.
- 5 January 2024
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 77, 215-219
A checklist intervention for pediatric emergency department transfer of care sign-outs
- 5 January 2024
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 77, 215-219
A checklist intervention for pediatric emergency department transfer of care sign-outs